Shares of Torrent Pharmaceuticals Ltd hit a 52-week high of Rs 2,742.60 on 6 March after the company announced receiving EIR from the USFDA.

In its regulatory filing, the company said that the US Food and Drug Administration (USFDA) had issued an establishment inspection report (EIR) for the company’s Oral-Oncology manufacturing facility in Bileshwarpura, Gujarat and added that the inspection had been closed successfully by the US regulator.

A pre-approval inspection was conducted by the USFDA at the company’s Oral-oncology manufacturing facility in Gujarat between 5 December 2023 and 11 December 2023.

Torrent Pharma is a flagship company of the Torrent Group and has been ranked in the top 10 of the Indian Pharmaceuticals market.

Earlier on 2 February, the company had declared an interim dividend of Rs 22 per share of Rs 5 fully paid up, which will be paid on or around 23 February.

At 3:30 pm, the shares of Torrent Pharma closed 1.24% higher at Rs 2,694.95 on NSE.